Moderna’s Historic Surge on Melanoma Vaccine Data
Shares of Moderna (MRNA) soared 101% on Wednesday, August 19, 2026, marking the stock’s biggest intraday gain on record. The biotech firm, alongside partner Merck & Co., announced that its personalized cancer vaccine, when combined with Merck’s Keytruda, significantly reduced melanoma recurrence in a large, late-stage trial. The study also met a key secondary goal of preventing tumors from spreading to new areas of the body, according to a joint statement released Wednesday.
This unprecedented move reflects investor optimism about the vaccine’s potential to transform cancer treatment. The stock’s surge added roughly $30 billion to Moderna’s market capitalization, based on pre-announcement levels, underscoring the magnitude of the clinical breakthrough.
Why the Vaccine Data Reshapes Moderna’s Growth Outlook
The positive late-stage data validates Moderna’s mRNA platform beyond COVID-19, opening a new revenue stream that could diversify its pipeline. Analysts note that if the vaccine gains regulatory approval, it could address a melanoma market estimated at over $2 billion annually, with potential expansion into other solid tumors.
Merck’s Keytruda, already a blockbuster with $25 billion in 2025 sales, could see extended use in combination therapies, benefiting both companies. However, the road to approval remains long, with late-stage trials still ongoing and regulatory submissions likely not until 2027.
Estee Lauder Beats Q4 Estimates, Lifts Fiscal 2027 Guidance
In contrast, Estee Lauder (EL) rallied after reporting fourth-quarter adjusted earnings per share and sales that topped consensus expectations. For the quarter ended June 30, 2026, adjusted EPS came in at $0.85 versus the $0.72 expected, while sales reached $4.1 billion against a $3.9 billion forecast.
The company’s fiscal 2027 organic sales growth guidance midpoint of 5% and adjusted EPS midpoint of $5.60 both exceeded Street views of 4% and $5.40, respectively. Management attributed the strength to robust demand in Asia-Pacific and successful premium product launches.
What the Earnings Beat Signals for the Beauty Sector
Estee Lauder’s performance suggests resilience in the premium beauty market despite inflationary pressures. Competitors like L’Oreal and Coty may also benefit from similar trends, but Estee’s specific guidance implies confident management about holiday season sales.
Investors should watch whether Estee can sustain this momentum, given currency headwinds and potential supply chain disruptions. The company’s next earnings report, due in November, will reveal if the upbeat outlook translates into actual results.
La-Z-Boy Tumbles on Weak Q2 Sales Forecast
Meanwhile, La-Z-Boy (LZB) shares fell at the open after the furniture maker projected second-quarter sales below analyst estimates. The company guided to $480-$500 million in Q2 revenue, missing the consensus of $525 million, citing softer consumer demand in home furnishings.
This discrepancy highlights a broader slowdown in the housing-linked sector, as high mortgage rates continue to dampen spending. La-Z-Boy’s update contrasts with strong home improvement chains, suggesting a divergence in consumer priorities.
Looking ahead, the key data point to watch is Moderna’s regulatory submission timeline and any updates from the ongoing Phase 3 trial, as well as Estee Lauder’s holiday quarter performance, which will confirm or challenge its guidance.
Comments are closed.